Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...
Հիմնական հեղինակներ: | Chakrabarti, S, Hale, G, Waldmann, H |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2004
|
Նմանատիպ նյութեր
-
Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
: Watson, C, և այլն
Հրապարակվել է: (2004) -
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
: Hale, G, և այլն
Հրապարակվել է: (2002) -
The evolving role of alemtuzumab (Campath-1H) in renal transplantation
: Phuong-Thu T Pham, և այլն
Հրապարակվել է: (2008-12-01) -
T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
: Hale, G, և այլն
Հրապարակվել է: (1988) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
: Clatworthy, MR, և այլն
Հրապարակվել է: (2009)